Category: Drug

BioNTech SE (BNTX) 9/22/21 9:30 AM

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Crystal Coma rare sativa-dominant hybrid

Crystal Coma is a rare sativa-dominant hybrid from California that induces deep, trance-like effects. Its name foreshadows the debilitating relaxation to come, a long-lasting calm that shuts off mental overactivity. Pastel green breaks through this sativa’s thick blanket of crystal trichomes that contributes to its staggeringly high THC content of up to 26 percent. 

Merck & Co. ~ ArQule $2.7 Billion

ArQule shares surge after the cancer drug specialists agreed to a $2.7 billion takeover bid from Merck & Co.

Merck & Co. said Monday that it will acquire oncology specialist ArQule in a $2.7 billion deal that marks the latest in a string of takeovers in the cancer drug sector. Merck said it will pay $20 a share for Woburn, Massachusetts-based ArQule, a premium of more than $10 to the stock’s closing price of $9.66 Friday on the Nasdaq. The group, which focuses on research and development of targeted therapeutics to treat cancers and rare diseases, will be merged into the broader Merck & Co., the companies said.

“We are proud that Merck has recognized the contributions that ArQule, together with its scientific collaborators, has made to the field of precision medicine in oncology with ARQ 531 for the treatment of B-cell malignancies and with the rest of our clinical-stage pipeline,” said ArQuel CEO Paolo Pucci. “With this agreement, ArQule’s pipeline will benefit from Merck’s vast capabilities and determined engagement to benefit the patients who we have always strived to serve.”  

ArQule shares were indicated some 103% higher in early trading following news of the Merck takeover to change hands at $19.64 each. Merck shares, meanwhile, were marked 0.57% lower at $88.34 each.

Merck’s move to buy ArQule follows a $2.5 billion takeover of San Diego, California-based Synthorx by France’s Sanofi SA earlier Monday. Sanofi said it will pay $68 a share for Synthorx, which focuses on cancer and autoimmune disorder treatments, in a deal that will bolster its immuno-oncology pipeline. 


CBD ~ Cannabidiol a popular natural remedy

Better known as CBD, it is one of the 104 chemical compounds known as cannabinoids found in the cannabis or marijuana plant, Cannabis sativa .

Tetrahydrocannabinol (THC) is the main psychoactive cannabinoid found in cannabis, and causes the sensation of getting “high” that’s often associated with marijuana. However, unlike THC, CBD is not psychoactive.

This quality makes CBD an appealing option for those who are looking for relief from pain and other symptoms without the mind-altering effects of marijuana or certain pharmaceutical drugs.

CBD oil is made by extracting CBD from the cannabis plant, then diluting it with a carrier oil like coconut or hemp seed oil.

It’s gaining momentum in the health and wellness world, with some scientific studies confirming it may help treat a variety of ailments like chronic pain and anxiety.

Curaleaf Products

Live Life Well

Curaleaf shares CURLF, +7.18%  rose 3.3%, after the company said CVSCVS, +0.07%  is already selling products including creams, sprays, roll-ons, lotions and salves in eight states.

Curaleaf is the largest national retail dispensary brand in the U.S., as well as a premium mainstream cannabis brand available in multiple states and product formats:

  • Vape Oils & Concentrates
  • Flower, Pre-rolls & Flower Pods
  • Topical Lotions
  • Capsules & Tinctures
  • Mints & Lozenges
  • Edibles

LA Confidential

By combining a legendary Los Angeles-area Afghani with another choice Afghani specimen, DNA Genetics created a very potent indica hybrid in L.A. Confidential.  The plant has massive dark green fan leaves, is disease and mold-resistant, and yields well with proper care.  The old school sweet and spicy Afghani taste brings to mind the mother OG Affie.

OG L.A. Affie x Afghan

Musky and spicy, it recalls its Afghani roots with the aroma

Spicy and hashy, there is a light sweetness at times that brings to mind pressed hash

This is a very relaxing and narcotic indica — even in smaller doses, most users will find themselves sinking into the couch with a smile on their face for quite a while.

LA Confidential Indica

LA Confidential is known as a very popular and successful strain. Its buds have a frosty, lime green appearance and little purple leaves. The taste is smooth and piney, with a classic skunky aroma that does not linger for too long. Overall, LA Confidential is a well-rounded strain that delivers a fast-approaching sensation that is both psychedelic and super calming on the mind and body. For newer patients seeking relief, LA Confidential can both lull you to sleep and treat acute pain. 

Aurora Cannabis (ACB)

Aurora Cannabis

Aurora Cannabis Inc. is a Canadian licensed cannabis producer, headquartered in Edmonton. It trades on the Toronto Stock Exchange as ACB.[2] As of late September 2018, Aurora Cannabis had eight licensed production facilities, five sales licenses, and operations in 18 countries. It had a funded capacity of over 500,000 kilograms of cannabis production per annum. Aurora is the second largest cannabis company in the world by market capitalization, after Canopy Growth Corporation. The company began trading on the NYSE on October 23rd, 2018

At close 3/09/2019


Our award-winning support staff, experienced cultivators, and network of healthcare practitioners are here to help remove barriers to medical cannabis. We’re honored to be part of a movement that’s helping Canadians across the country access their medicine; and as we grow we will continue to provide patients with reliable access to safe, consistent, and effective medical cannabis.

Guerrilla Glue


Original Glue (GG4), developed by GG Strains, is a potent hybrid strain that delivers heavy-handed euphoria and relaxation, leaving you feeling “glued” to the couch. Its chunky, resin-covered buds fill the room with pungent earthy and sour aromas inherited from its parent strains, Chem’s SisterSour Dubb, and Chocolate Diesel. Taking first place in both the Michigan and Los Angeles 2014 Cannabis Cups as well as the High Times Jamaican World Cup, this multiple award-winning hybrid’s supremacy is no longer a secret, and consumers will search far and wide to get their hands sticky with Original Glue (GG4).